Clinical Trial

CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 27, 2023 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, open-label, multicenter, phase II study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency. It is planned to enroll patients with PTEN deficiency advanced solid tumors of different tumor types (PTEN deficiency gastric cancer, prostate cancer, endometrial cancer, colorectal cancer, lung cancer, breast cancer and melanoma etc.) to evaluate the preliminary efficacy, safety and pharmacokinetic profile of CVL237 tablets in patients with PTEN deficiency advanced solid tumors of different tumor types.
Trial Details
NCT Number NCT06183736
Lead Sponsor Convalife (Shanghai) Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 98 participants
Start Date 2023-12-20
Primary Completion 2025-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2023-12-27